Mike Hubank
@generoom.bsky.social
Clinical Genomics in the UK.
Scientific Director of Clinical Genomics at the Royal Marsden and North Thames GLH. Prof of Translational Genomics at ICR, London
Scientific Director of Clinical Genomics at the Royal Marsden and North Thames GLH. Prof of Translational Genomics at ICR, London
Reposted by Mike Hubank
Real-world data is a hot topic with medical regulators and payers in oncology. Here is our analysis comparing a change in induction regimens in multiple myeloma in a public healthcare system, using real-world MRD measurement.
www.clinical-lymphoma-myeloma-leukemia.com/article/S215...
www.clinical-lymphoma-myeloma-leukemia.com/article/S215...
Evaluating the real-world value of daratumumab addition to multiple myeloma induction therapy by real-world minimal residual disease assessment and extended genetic profiling
Daratumumab, bortezomib, thalidomide, and dexamethasone (Dara-VTd) is the current
standard of care in Europe based on the CASSIOPEIA study, which demonstrated improved
depth of response and progressio...
www.clinical-lymphoma-myeloma-leukemia.com
November 16, 2025 at 7:10 AM
Real-world data is a hot topic with medical regulators and payers in oncology. Here is our analysis comparing a change in induction regimens in multiple myeloma in a public healthcare system, using real-world MRD measurement.
www.clinical-lymphoma-myeloma-leukemia.com/article/S215...
www.clinical-lymphoma-myeloma-leukemia.com/article/S215...
Reposted by Mike Hubank
Calling cancer data scientists! 📊 💽 🧮
We have a number of open positions in our core facility @icr.ac.uk These are bioinformatician staff scientist like roles to work on exciting single cell, spatial & other genomics data from across our Institute. A PhD is required. jobs.icr.ac.uk/vacancies/13...
We have a number of open positions in our core facility @icr.ac.uk These are bioinformatician staff scientist like roles to work on exciting single cell, spatial & other genomics data from across our Institute. A PhD is required. jobs.icr.ac.uk/vacancies/13...
Data Scientist in Sutton | The Institute of Cancer Research
View details and apply for this Data Scientist vacancy in Sutton.
Salary : Salary range £39,805 to £53,500 (Dependent on experience )
Reporting to: Professor Trevor Gra...
jobs.icr.ac.uk
November 13, 2025 at 2:59 PM
Calling cancer data scientists! 📊 💽 🧮
We have a number of open positions in our core facility @icr.ac.uk These are bioinformatician staff scientist like roles to work on exciting single cell, spatial & other genomics data from across our Institute. A PhD is required. jobs.icr.ac.uk/vacancies/13...
We have a number of open positions in our core facility @icr.ac.uk These are bioinformatician staff scientist like roles to work on exciting single cell, spatial & other genomics data from across our Institute. A PhD is required. jobs.icr.ac.uk/vacancies/13...
Reposted by Mike Hubank
Very interesting day at the genomics England long read summit. And great to catch up with @generoom.bsky.social and more!
November 10, 2025 at 6:36 PM
Very interesting day at the genomics England long read summit. And great to catch up with @generoom.bsky.social and more!
Reposted by Mike Hubank
1/ 🚨New paper in Nature Genetics
Genetic factors are associated with the educational fields people study, from arts to engineering.
Article: www.nature.com/articles/s41...
FAQ: www.thehastingscenter.org/genomic-find...
Genetic factors are associated with the educational fields people study, from arts to engineering.
Article: www.nature.com/articles/s41...
FAQ: www.thehastingscenter.org/genomic-find...
Genetic associations with educational fields - Nature Genetics
Genome-wide analyses of 10 educational fields identify 17 associated loci. Analysis of genetic clustering across specializations identifies two key dimensions that show genetic overlap with personalit...
www.nature.com
November 4, 2025 at 10:23 AM
1/ 🚨New paper in Nature Genetics
Genetic factors are associated with the educational fields people study, from arts to engineering.
Article: www.nature.com/articles/s41...
FAQ: www.thehastingscenter.org/genomic-find...
Genetic factors are associated with the educational fields people study, from arts to engineering.
Article: www.nature.com/articles/s41...
FAQ: www.thehastingscenter.org/genomic-find...
Reposted by Mike Hubank
For 61 years the #BBCWorldService has been broadcasting the latest in science via its weekly Science in Action programme. That dies in the next half hour, with this final edition, reflecting on the fall in trust in expertise driven by malign interests over recent years.
October 30, 2025 at 8:20 PM
For 61 years the #BBCWorldService has been broadcasting the latest in science via its weekly Science in Action programme. That dies in the next half hour, with this final edition, reflecting on the fall in trust in expertise driven by malign interests over recent years.
Reposted by Mike Hubank
Even chimpanzees think rationally and weigh the evidence when making a choice ;-)
@science.org
www.science.org/doi/10.1126/...
@science.org
www.science.org/doi/10.1126/...
Chimpanzees rationally revise their beliefs
The selective revision of beliefs in light of new evidence has been considered one of the hallmarks of human-level rationality. However, tests of this ability in other species are lacking. We examined...
www.science.org
October 31, 2025 at 1:52 AM
Even chimpanzees think rationally and weigh the evidence when making a choice ;-)
@science.org
www.science.org/doi/10.1126/...
@science.org
www.science.org/doi/10.1126/...
Reposted by Mike Hubank
You've got just a few days left to submit your proposal to join us as a new Group Leader
📅 Applications close 2nd November
Package includes:
🪙Multi-year funding
🧪Core Facility Access
🥼 #Postdoc & #PhD positions
🤝Mentorship
Visit our website to apply:
www.cruk.manchester.ac.uk/career/new-g...
📅 Applications close 2nd November
Package includes:
🪙Multi-year funding
🧪Core Facility Access
🥼 #Postdoc & #PhD positions
🤝Mentorship
Visit our website to apply:
www.cruk.manchester.ac.uk/career/new-g...
October 30, 2025 at 11:47 AM
You've got just a few days left to submit your proposal to join us as a new Group Leader
📅 Applications close 2nd November
Package includes:
🪙Multi-year funding
🧪Core Facility Access
🥼 #Postdoc & #PhD positions
🤝Mentorship
Visit our website to apply:
www.cruk.manchester.ac.uk/career/new-g...
📅 Applications close 2nd November
Package includes:
🪙Multi-year funding
🧪Core Facility Access
🥼 #Postdoc & #PhD positions
🤝Mentorship
Visit our website to apply:
www.cruk.manchester.ac.uk/career/new-g...
Well balanced explanation from Beth Torr of who we test for germline #BRCA mutations and why.
We are proud to be delivering this testing in the #RoyalMarsden lab at the #NHS North Thames Genomic lab hub.
We are proud to be delivering this testing in the #RoyalMarsden lab at the #NHS North Thames Genomic lab hub.
BRCA gene testing can identify cancer risk, but access is limited.
A new digital pathway from the ICR is expanding testing in high-risk groups by making the process more efficient and cost-effective.
In the longer term, this approach could lead to better patient outcomes.
More from us here ⬇️
A new digital pathway from the ICR is expanding testing in high-risk groups by making the process more efficient and cost-effective.
In the longer term, this approach could lead to better patient outcomes.
More from us here ⬇️
Could expanding BRCA gene testing save lives in breast and ovarian cancer?
Could expanding BRCA gene testing save lives in breast and ovarian cancer?
www.icr.ac.uk
October 28, 2025 at 9:36 AM
Well balanced explanation from Beth Torr of who we test for germline #BRCA mutations and why.
We are proud to be delivering this testing in the #RoyalMarsden lab at the #NHS North Thames Genomic lab hub.
We are proud to be delivering this testing in the #RoyalMarsden lab at the #NHS North Thames Genomic lab hub.
Reposted by Mike Hubank
Improved diagnostic tools are crucial for early detection of cancer and, therefore, better treatment.
At The Festival of Genomics and Biodata in London in January, we are dedicating a theatre to this very topic.
Get your ticket here: hubs.la/Q03JMxrd0 #FOG2026
At The Festival of Genomics and Biodata in London in January, we are dedicating a theatre to this very topic.
Get your ticket here: hubs.la/Q03JMxrd0 #FOG2026
October 22, 2025 at 10:01 AM
Improved diagnostic tools are crucial for early detection of cancer and, therefore, better treatment.
At The Festival of Genomics and Biodata in London in January, we are dedicating a theatre to this very topic.
Get your ticket here: hubs.la/Q03JMxrd0 #FOG2026
At The Festival of Genomics and Biodata in London in January, we are dedicating a theatre to this very topic.
Get your ticket here: hubs.la/Q03JMxrd0 #FOG2026
Reposted by Mike Hubank
Whole genome sequencing with AVITI and NovaSeq X Plus reveals comparable performance with contextual biases. #Sequencing #Benchmarking #Aviti #NovaSeq @biorxiv-genomic.bsky.social
www.biorxiv.org/content/10.1...
www.biorxiv.org/content/10.1...
October 22, 2025 at 10:30 AM
Whole genome sequencing with AVITI and NovaSeq X Plus reveals comparable performance with contextual biases. #Sequencing #Benchmarking #Aviti #NovaSeq @biorxiv-genomic.bsky.social
www.biorxiv.org/content/10.1...
www.biorxiv.org/content/10.1...
Am I being cynical, or is it more than a coincidence that Grail announce a £300m private finance deal days after bagging gushing media reports based on selective publicity from the frankly disappointing US Galleri trial?
grail.com/press-releas...
grail.com/press-releas...
GRAIL, Inc. Announces $325.0 Million Private Placement Financing - GRAIL
MENLO PARK, Calif. – Oct. 20, 2025 — GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that it has entered into a securitie...
grail.com
October 22, 2025 at 10:33 AM
Am I being cynical, or is it more than a coincidence that Grail announce a £300m private finance deal days after bagging gushing media reports based on selective publicity from the frankly disappointing US Galleri trial?
grail.com/press-releas...
grail.com/press-releas...
Reposted by Mike Hubank
What did the largest trial of an early detection of cancer blood test show?
erictopol.substack.com/p/the-larges...
erictopol.substack.com/p/the-larges...
The Largest Study of a Multi-Cancer Early Detection Blood Test
Reviewing the new data and the "liquid biopsy" field
erictopol.substack.com
October 21, 2025 at 1:36 PM
What did the largest trial of an early detection of cancer blood test show?
erictopol.substack.com/p/the-larges...
erictopol.substack.com/p/the-larges...
A population cancer screening test must be cheap, specific, and sensitive.
Unless specificity is 100%, there needs to be a more sensitive and more specific confirmation test.
From what I have seen, #Galleri still meets none of these criteria adequately and is unlikely to be good value for the #NHS
Unless specificity is 100%, there needs to be a more sensitive and more specific confirmation test.
From what I have seen, #Galleri still meets none of these criteria adequately and is unlikely to be good value for the #NHS
www.bbc.com/news/article...
Harpal Kumar said the results were very compelling. That's because he is a businessman with a huge financial conflict of interest and a poor understanding of the science required to determine whether a screening test is useful.
Harpal Kumar said the results were very compelling. That's because he is a businessman with a huge financial conflict of interest and a poor understanding of the science required to determine whether a screening test is useful.
Galleri test: Exciting results from blood test for 50 cancers
The Galleri test looks for fragments of DNA that have broken off a tumour and are circulating in the blood.
www.bbc.com
October 18, 2025 at 5:32 PM
Reposted by Mike Hubank
(COI: I am a longstanding consultant and shareholder of Oxford nanopore). This has been cooking away (the scaling of DNA tech is... that there is a lot of space at the bottom - and also time / Hz space) and nice to see the price for long reads (with methylation!) continue to drop. Whoop!
October 15, 2025 at 4:34 PM
(COI: I am a longstanding consultant and shareholder of Oxford nanopore). This has been cooking away (the scaling of DNA tech is... that there is a lot of space at the bottom - and also time / Hz space) and nice to see the price for long reads (with methylation!) continue to drop. Whoop!
Reposted by Mike Hubank
We have two fantastically well-funded #PhD studentships available through the @evomg-dn.bsky.social #EU doctoral network (led by brilliant @mirimiam.bsky.social, @crg.eu). These enable students to move to the UK and come and work with us @icr.ac.uk to exploit #cancer #evolution for patient benefit.
October 14, 2025 at 8:21 PM
We have two fantastically well-funded #PhD studentships available through the @evomg-dn.bsky.social #EU doctoral network (led by brilliant @mirimiam.bsky.social, @crg.eu). These enable students to move to the UK and come and work with us @icr.ac.uk to exploit #cancer #evolution for patient benefit.
Reposted by Mike Hubank
Big step forward in #BloodCancer care 🚨
ICR scientists found that combining DNA + RNA tests predicts early relapse in multiple myeloma far better than DNA alone — catching 84% of cases. The Royal Marsden will offer RNA testing from 2026.
Earlier diagnosis = better treatment plans & outcomes.
ICR scientists found that combining DNA + RNA tests predicts early relapse in multiple myeloma far better than DNA alone — catching 84% of cases. The Royal Marsden will offer RNA testing from 2026.
Earlier diagnosis = better treatment plans & outcomes.
October 13, 2025 at 8:43 AM
Big step forward in #BloodCancer care 🚨
ICR scientists found that combining DNA + RNA tests predicts early relapse in multiple myeloma far better than DNA alone — catching 84% of cases. The Royal Marsden will offer RNA testing from 2026.
Earlier diagnosis = better treatment plans & outcomes.
ICR scientists found that combining DNA + RNA tests predicts early relapse in multiple myeloma far better than DNA alone — catching 84% of cases. The Royal Marsden will offer RNA testing from 2026.
Earlier diagnosis = better treatment plans & outcomes.
Reposted by Mike Hubank
I am hiring! - looking for a Staff Scientist to co-run my research group with me. Staff Scientist is a senior professional scientist role at EMBL. Please forward to people you might know who could be interested! embl.wd103.myworkdayjobs.com/en-US/EMBL/j...
Staff Scientist
About EMBL-EBI EMBL’s European Bioinformatics Institute is a data powerhouse, utilised on a global scale to advance scientific discovery through bioinformatics and solutions to some of the world’s mos...
embl.wd103.myworkdayjobs.com
October 10, 2025 at 7:30 AM
I am hiring! - looking for a Staff Scientist to co-run my research group with me. Staff Scientist is a senior professional scientist role at EMBL. Please forward to people you might know who could be interested! embl.wd103.myworkdayjobs.com/en-US/EMBL/j...
Reposted by Mike Hubank
A short thread. For years, I have been surprised by how much confusion our discovery of clones carrying cancer-driver mutations in normal tissues has caused in the cancer community. Typical questions like: (1) if you see these mutations in normal cells, are they really cancer drivers?... [1/4]
Our latest work is out in Nature today. In this paper, we introduce an improved version of NanoSeq, a duplex sequencing protocol with <5 errors per billion bp in single DNA molecules, and use it to study the somatic mutation landscape of oral epithelium in >1000 people www.nature.com/articles/s41...
Somatic mutation and selection at population scale - Nature
A new version of nanorate DNA sequencing, with an error rate lower than five errors per billion base pairs and compatible with whole-exome and targeted capture, enables epidemiological-scale studies of somatic mutation and selection and the generation of high-resolution selection maps across coding and non-coding sites for many genes.
www.nature.com
October 9, 2025 at 3:29 PM
A short thread. For years, I have been surprised by how much confusion our discovery of clones carrying cancer-driver mutations in normal tissues has caused in the cancer community. Typical questions like: (1) if you see these mutations in normal cells, are they really cancer drivers?... [1/4]
Reposted by Mike Hubank
Prof Sanjay Popat shared an encouraging outlook on ALK+ #lungcancer treatments at our conference last weekend.
Huge thanks to him and to all our experts - we couldn’t make this conference happen every year without you. It’s so important that our community stays informed & empowered. 💙 #LCSM
Huge thanks to him and to all our experts - we couldn’t make this conference happen every year without you. It’s so important that our community stays informed & empowered. 💙 #LCSM
October 5, 2025 at 7:56 AM
Prof Sanjay Popat shared an encouraging outlook on ALK+ #lungcancer treatments at our conference last weekend.
Huge thanks to him and to all our experts - we couldn’t make this conference happen every year without you. It’s so important that our community stays informed & empowered. 💙 #LCSM
Huge thanks to him and to all our experts - we couldn’t make this conference happen every year without you. It’s so important that our community stays informed & empowered. 💙 #LCSM
Disease predicting #polygenic risk scores #PRS do not predict the severity of disease.
Susceptibility #PRS will therefore not stratify the most economically-demanding populations for focussed intervention.
So, simple #PRS application will not be a shortcut to effectively-focussed healthcare.
Susceptibility #PRS will therefore not stratify the most economically-demanding populations for focussed intervention.
So, simple #PRS application will not be a shortcut to effectively-focussed healthcare.
🧬💥 Do the genetics that make you develop a disease also help you survive it? Not much.
Our new study in Nature Genetics including 9 disease and 7 biobanks shows:
• Susceptibility variants ≠ survival
• PRSs for onset weak at predicting progression
• Lifespan PRS predicts survival better
Our new study in Nature Genetics including 9 disease and 7 biobanks shows:
• Susceptibility variants ≠ survival
• PRSs for onset weak at predicting progression
• Lifespan PRS predicts survival better
September 30, 2025 at 2:12 PM
Disease predicting #polygenic risk scores #PRS do not predict the severity of disease.
Susceptibility #PRS will therefore not stratify the most economically-demanding populations for focussed intervention.
So, simple #PRS application will not be a shortcut to effectively-focussed healthcare.
Susceptibility #PRS will therefore not stratify the most economically-demanding populations for focussed intervention.
So, simple #PRS application will not be a shortcut to effectively-focussed healthcare.
Reposted by Mike Hubank
PhD opportunity available on epigenomics/trasncriptomics as part of the network of clinicians and researchers working in glioblastoma research at @uniofnottingham.bsky.social Using a wide range of tech and methods but definitely long reads @nanoporetech.com - more at lnkd.in/eBtrtZiM
LinkedIn
This link will take you to a page that’s not on LinkedIn
lnkd.in
September 25, 2025 at 5:42 PM
PhD opportunity available on epigenomics/trasncriptomics as part of the network of clinicians and researchers working in glioblastoma research at @uniofnottingham.bsky.social Using a wide range of tech and methods but definitely long reads @nanoporetech.com - more at lnkd.in/eBtrtZiM
Reposted by Mike Hubank
Excited to announce that our PearlAI DependANT tool for identifying targeted treatments for patients with Cancer of Unknown Primary is one of the 48 projects funded by the UKRI Proof of Concept programme !!
www.ukri.org/news/48-proj...
www.ukri.org/news/48-proj...
48 projects backed to turn cutting-edge research into businesses
UKRI backs cutting-edge projects, from home tests for endometriosis to AI for accessible travel, to grow into market-leading products and services.
www.ukri.org
September 25, 2025 at 8:48 AM
Excited to announce that our PearlAI DependANT tool for identifying targeted treatments for patients with Cancer of Unknown Primary is one of the 48 projects funded by the UKRI Proof of Concept programme !!
www.ukri.org/news/48-proj...
www.ukri.org/news/48-proj...
Reposted by Mike Hubank
Exciting news - we are recruiting new Group Leaders! 🥼
We are seeking to appoint exceptional early-career scientists & clinician scientists as #GroupLeaders to develop bold, innovative, high-impact #CancerResearch programmes
Full details on our website: www.cruk.manchester.ac.uk/career/new-g...
We are seeking to appoint exceptional early-career scientists & clinician scientists as #GroupLeaders to develop bold, innovative, high-impact #CancerResearch programmes
Full details on our website: www.cruk.manchester.ac.uk/career/new-g...
Group Leader Recruitment at the Cancer Research UK Manchester Institute
YouTube video by CRUK Manchester Institute
youtu.be
September 24, 2025 at 3:03 PM
Exciting news - we are recruiting new Group Leaders! 🥼
We are seeking to appoint exceptional early-career scientists & clinician scientists as #GroupLeaders to develop bold, innovative, high-impact #CancerResearch programmes
Full details on our website: www.cruk.manchester.ac.uk/career/new-g...
We are seeking to appoint exceptional early-career scientists & clinician scientists as #GroupLeaders to develop bold, innovative, high-impact #CancerResearch programmes
Full details on our website: www.cruk.manchester.ac.uk/career/new-g...
Reposted by Mike Hubank
Scientists discover a new drug target to treat #PancreaticCancer.
In the lab, blocking the SPP1 protein completely stopped pancreatic cancer from spreading to the liver and lungs.
Read more about the findings, published in @nature.com ⬇️
www.icr.ac.uk/about-us/icr...
In the lab, blocking the SPP1 protein completely stopped pancreatic cancer from spreading to the liver and lungs.
Read more about the findings, published in @nature.com ⬇️
www.icr.ac.uk/about-us/icr...
September 24, 2025 at 3:10 PM
Scientists discover a new drug target to treat #PancreaticCancer.
In the lab, blocking the SPP1 protein completely stopped pancreatic cancer from spreading to the liver and lungs.
Read more about the findings, published in @nature.com ⬇️
www.icr.ac.uk/about-us/icr...
In the lab, blocking the SPP1 protein completely stopped pancreatic cancer from spreading to the liver and lungs.
Read more about the findings, published in @nature.com ⬇️
www.icr.ac.uk/about-us/icr...
Reposted by Mike Hubank
In the early years of my PhD I remember being asked if we'd ever treat or cure diseases like HIV or Huntington's. I remember saying maybe, but not knowing if I believed. Seeing research pay off as real impact on human lives is - incredible.
www.bbc.com/news/article...
www.bbc.com/news/article...
www.bbc.com/news/article...
www.bbc.com/news/article...
Huntington's disease successfully treated for first time
One of the most devastating diseases finally has a treatment that can slow its progression and transform lives, tearful doctors tell BBC.
www.bbc.com
September 24, 2025 at 12:41 PM
In the early years of my PhD I remember being asked if we'd ever treat or cure diseases like HIV or Huntington's. I remember saying maybe, but not knowing if I believed. Seeing research pay off as real impact on human lives is - incredible.
www.bbc.com/news/article...
www.bbc.com/news/article...
www.bbc.com/news/article...
www.bbc.com/news/article...